Delving into the Latest Updates on Gimeracil with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

5-Chloro-2,4-dihydroxypyridine, 5-Chloro-4-hydroxy-2-pyridone, Gimeracil (JAN/INN)

+ [3]

Target-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization-

Active Organization

Shandong New Time Pharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

RegulationSpecial Review Project (CN)

Login to view timeline

Structure/Sequence

Molecular FormulaC5H4ClNO2

InChIKeyZPLQIPFOCGIIHV-UHFFFAOYSA-N

CAS Registry103766-25-2

A multicenter, randomized, phase III clinical study comparing the combination of radiotherapy with Tegafur, Gimeracil, and Oteracil Potassium (TS-1) and Tislelizumab to the combination of radiotherapy with TS-1 in elderly patients with locally advanced esophageal squamous cell carcinoma. - A multicenter, randomized, phase III clinical study comparing the combination of radiotherapy with Tegafur, Gimeracil, and Oteracil Potassium (TS-1) and Tislelizumab to the combination of radiotherapy with TS-1 in elderly patients with locally advanced esophageal squamous cell carcinoma.

Start Date01 Mar 2024

Sponsor / Collaborator

Henan Cancer Hospital

JPRN-UMIN000043646

/ RecruitingNot ApplicableIIT

Long term follow-up protocol of Peri-operative chemotherapy with intraperitoneal and intravenous Paclitaxel plus TS-1 for serosa positive gastric cancer patients phase 2 study - Long term follow-up of GAPS study

Start Date01 Sep 2019

Sponsor / Collaborator

Kindai University

JPRN-jRCTs071180083

/ CompletedPhase 1IIT

Feasibility study of adjuvant chemotherapy with cisplatin(CDDP) and TS-1 in followed by alternate-day treatment with TS-1 in patients with completely resected pathological II-IIIA non small cell lung cancer - None

Start Date29 Mar 2019

Sponsor / Collaborator-

100 Clinical Results associated with Gimeracil

Login to view more data

100 Translational Medicine associated with Gimeracil

Login to view more data

100 Patents (Medical) associated with Gimeracil

Login to view more data

614

Literatures (Medical) associated with Gimeracil

01 Jan 2025·Journal of Chromatography B

Quantification of gimeracil, tegafur, and 5-FU in human plasma via LC-MS/MS with a simplified pretreatment using flow-through extraction

Article

Author: Kawahara, Masami ; Maeda, Shoko ; Watanabe, Norio ; Seike, Riko ; Gocho, Saori ; Inagaki, Masami ; Ando, Motozumi

Gimeracil, a component in S-1 (an oral anticancer agent comprising tegafur, a prodrug of 5-fluorouracil (5-FU), potassium oxonate, and gimeracil), inhibits metabolic enzymes, thereby impeding 5-FU degradation. Therefore, the blood level of gimeracil is closely associated with the disposition of 5-FU, and quantification of gimeracil can provide important information if a case shows an inappropriate 5-FU blood concentration. Nevertheless, methods for quantifying gimeracil in human plasma are rarely reported. Herein, we aimed to develop a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for quantifying gimeracil, in addition to tegafur and 5-FU, levels in human plasma using a clinically applicable simplified pretreatment process and faster elution time. Hence, an acetamide-functionalized monolith silica disk-packed spin column was used to extract gimeracil and internal standard (IS; nicotinamide), whereas diatomaceous earth-based solid phase for liquid-liquid extraction was used to extract tegafur, 5-FU, and IS (5-chlorouracil) from plasma. Each extract was analyzed within 4 min of elution via LC-MS/MS using a shared LC column and mobile phase. Accuracy and precision analyses indicated lower limits of quantification of 5, 10, and 2 ng/mL for gimeracil, tegafur, and 5-FU, respectively. The calibration curves showed good linearity between 5 and 500 ng/mL for gimeracil, 10 and 5000 ng/mL for tegafur, and 2 and 1000 ng/mL for 5-FU. We confirmed that the levels of all analytes in the plasma of patients with cancer undergoing S-1-inclusive therapy were within the calibration range for each analyte. Thus, this newly developed quantification method is likely to be useful for optimization of S-1 therapy.

01 Dec 2024·Gan to kagaku ryoho. Cancer & chemotherapy

[A Case of Breast Cancer Recurrence 32 Years after Primary Surgery].

Article

Author: Yoshioka, Yuichiro ; Tanaka, Junichiro ; Kubota, Yoshiro ; Sato, Shun ; Kondo, Yuji ; Nirei, Takako

An 80-year-old woman presented with blood-stained sputum. Computed tomography revealed the presence of multiple lung nodules. The patient underwent surgery for left breast cancer at 48 years of age. A transbronchial lung biopsy was performed to identify the primary tumor. The pathological diagnosis was adenocarcinoma and immunohistochemical staining indicated that the lung nodules were breast cancer metastases. Positron emission tomography revealed multiple metastases to the bones, skin, peritoneum, and mesenteric lymph nodes. The patient indicated that the quality of life was a critical factor in selecting therapy. Denosumab and an aromatase inhibitor were selected as the first-line systemic chemotherapies. The treatment resulted in tumor shrinkage that lasted for 3 years, after which the peritoneal metastases started to regrow. We recommended tegafur/gimeracil/oteracil as second-line chemotherapy, which the patient discontinued within 1 month because of severe side effects. We next administered fulvestrant, which resulted in the long-term shrinkage of most tumors without regrowth. This treatment did not negatively affect patients' quality of life. Some breast cancers recur ≥5 years after the primary surgery. Therefore, this is a very rare case of breast cancer recurrence with an interval of 32 years after the initial treatment.

05 Jul 2024·The Journal of Organic Chemistry

Unlocking Enantioselectivity: Synergy of 2-Pyridone and Chiral Amino Acids in Pd-Catalyzed β-C(sp³)–H Transformations

Article

Author: Mandal, Sucharita ; Mandal, Nilangshu ; Mondal, Partha ; Datta, Ayan

Enantioselective C(sp³)-H activation has garnered significant attention in synthetic and computational chemistry. Chiral transient directing groups (TDGs) hold promise for enabling Pd(II)-catalyzed enantioselective C(sp³)-H functionalization. Despite the interest in this strategy, it presents a challenge because the stereogenic center on the chiral TDG is frequently distant from the C-H bond, leading to a mixture of functionalized products. Our computational study on Pd(II)-catalyzed enantioselective β-C(sp³)-H arylation of aliphatic ketone with chiral amino acids provides a sustainable route to synthesizing complex chiral molecular scaffolds. The cooperative action of 2-pyridone derivatives and chiral amino acids is crucial in promoting the enantio-discriminating C-H activation, oxidative addition, and reductive elimination steps. Using 5-nitro-2-pyridone as the optimal external ligand demonstrates its ability to achieve the highest level of enantioselection. In contrast, the modeled 3,5-di((trifluoromethyl)sulfonyl)-2-pyridone ligand facilitates the most straightforward C-H activation. This study underscores the pivotal role of the alkyl substituent at the α-position of the amino acid (TDG) in altering enantioselectivity.

100 Deals associated with Gimeracil

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01846	-	-	DB09257

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NJLCG0804 (Pubmed) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	25	Tegafur+Gimeracil+Oteracil+Irinotecan Hydrochloride	(vhatfcguyy) = mwcgxaztqp yqgdkjwexw (ppeyeavezf, 63.9 - 95.5) View more	Positive	16 Aug 2022
Pubmed Manual	Not Applicable	Locally Advanced Gastric Carcinoma Neoadjuvant	96	Apatinib+Tegafur+Gimeracil+Oteracil+Oxaliplatin	(lubblywcaf) = the incidences of adverse events between the two groups were not different qqhfhwjwyn (rpyyjjtojh ) View more	Positive	11 Jul 2022
Pubmed Manual	Not Applicable	Locally Advanced Gastric Carcinoma Neoadjuvant	96	Oxaliplatin+Capecitabine		Positive	11 Jul 2022
JPRN-C000000416 (SELECT BC, ASCO2014)	Phase 3	Metastatic breast cancer First line	-	Taxane	(gqxhwhsmrd) = vgbazquuxr wjhdvpdwbz (xjsdfmfhai ) View more	Positive	20 May 2014
JPRN-C000000416 (SELECT BC, ASCO2014)	Phase 3	Metastatic breast cancer First line	-	TS-1	(gqxhwhsmrd) = bpuggcatgr wjhdvpdwbz (xjsdfmfhai ) View more	Positive	20 May 2014
ASCO2012	Not Applicable	Locally Advanced Unresectable Gastric Adenocarcinoma	1,372	TS-1 monotherapy	(aaceneaejl) = zqweipgkmu zgmqbqxfkf (mmihlqpydh, 10.6 - 17.9) View more	-	20 May 2012
ASCO2012	Not Applicable	Locally Advanced Unresectable Gastric Adenocarcinoma	1,372	TS-1/cisplatin	(aaceneaejl) = hahfvqzywf zgmqbqxfkf (mmihlqpydh, 14.4 - 17.9) View more	-	20 May 2012
ASCO2011	Phase 2	HER2-negative breast cancer Neoadjuvant	48	Doxorubicin/cyclophosphamide (AC) followed by docetaxel and TS-1 (DS)	(cmxrrrvlsc) = hwnwleolac diftvrxewy (whruwmwvif ) View more	-	20 May 2011
ASCO2010	Phase 1/2	Advanced Lung Non-Small Cell Carcinoma	23	TS-1 monotherapy	(lqwadnbsoe) = iaovgirfud vqtfdvgpcc (ualhsotycc ) View more	Positive	20 May 2010
ASCO2009	Not Applicable	Breast Cancer	40	TS-1	hjlibtggxx(erqgqzrwqr) = 6 of the 40 patients (15.0%) who received TS-1 did hand-foot syndrome (HFS), although 20 of the 40 patients (50.0%) who had received capecitabine, developed HFS. rxhhjexyth (phbuvultye )	Positive	20 May 2009
CJLSG0402 (ASCO2008)	Phase 1/2	Advanced Lung Non-Small Cell Carcinoma	-	TS-1 plus carboplatin	(jjmfnzqsbu) = tnsxzjejjm ejyisbajre (xuhcvutarr ) View more	-	20 May 2008
ASCO2007	Not Applicable	Neoplasms	147	Concurrent radiation therapy combined with UFT	scmlyswnqd(pcmaefheoj) = hhnhcbbsul bucdzrdqpm (wxxatzdwek )	Positive	20 Jun 2007
ASCO2007	Not Applicable	Neoplasms	147	Concurrent radiation therapy combined with TS-1	scmlyswnqd(pcmaefheoj) = ucfajfwxad bucdzrdqpm (wxxatzdwek )	Positive	20 Jun 2007
ASCO2007	Phase 2	Non-small cell lung cancer stage III	28	TS-1 plus cisplatin	(evtuvqomrg) = dpzxdfsdhg olvagcuvaw (skbnuivxbf, 79.1 - 98.7)	-	20 Jun 2007